The APPG has laid out a number of recommendations, which includes a number of measures to better support patients. People ...

Labels of all extended-release stimulants indicated for ADHD -- including certain formulations of amphetamine and ...

The ‘severe, persistent, and disruptive’ shortages often impact patients with ADHD, menopause and diabetes, a new report says ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

The findings also highlight how shortages severely impact patients with conditions like ADHD, menopause and diabetes.

Kids younger than 6 years on extended-release stimulants for ADHD may experience higher rates of side effects due to higher plasma exposures.

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

Medications for attention-deficit/hyperactivity disorder (ADHD) have some side effects that are common, while others are more ...

Instead, participants said, classifying methylphenidate a schedule 6 drug “ negatively impacts on treatment adherence ”. Our medicines regulator, the South African Health Products Regulatory Authority ...

The agency said it assessed data from clinical trials of extended-release formulations of amphetamine and methylphenidate for ADHD treatment, finding that, compared to older children, patients ...

A new generation of long-acting methylphenidate formulations are now available for the treatment of ADHD. This review analyzes 34 comparative studies to help inform clinical decision-making.

The use of stimulant medications to treat ADHD remains stigmatized to some degree. But these medications aren't only effective; they may even promote brain growth.